Epidemiology of metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis and associated cardiometabolic factors in adults in China (2013-2023): A systematic review and meta-analysis

Table 1 Prevalence of metabolically dysfunction-associated steatotic liver disease in different populations in China

Population	MASLD prevalence % (95%CI)
Overall	30.4 (29.4-31.3)
Male	35.4 (34.0-36.7)
Age
< 45 years	27.2 (25.1-29.3)
45-65 years	33.1 (31.8-34.4)
> 65 years	32.1 (29.2-35.0)
Locations
North China	30.7 (29.5-40.1)
South China	30.1 (28.8-31.4)
Regions
Northeast	35.2 (31.8-38.7)
East	30.7 (29.0-32.5)
Southwest	23.9 (20.1-28.1)
North	31.4 (30.0-32.9)
South Central	30.6 (29.1-32.2)
Northwest	28.1 (25.0-31.4)
Study periods
Before 2010	27.6 (25.0-30.2)
2010-2014	28.6 (26.8-30.4)
2015-2019	31.7 (30.0-33.4)
After 2019	36.5 (33.5-39.6)
BMI (kg/m2)
< 18.5	2.7 (1.3-4.5)
18.5-23.9	12.2 (10.5-14.0)
24.0-27.9	42.5 (39.5-45.6)
> 28.0	68.4 (62.3-74.1)

MASLD: Metabolic dysfunction-associated steatotic liver disease; CI: Confidence interval; BMI: Body mass index.